Biophore applies to DCGI for emergency-use approval for COVID-19 treatment drug
The Hindu
The company plans to commence commercial production of the product immediately after the approval is received, the Hyderabad-based firm said.
Biophore India Pharmaceuticals on Friday said it has applied to the Drugs Controller General of India (DCGI) for obtaining emergency-use approval for Aviptadil, used in the treatment of moderate to severe cases of . The Hyderabad-based firm said it has developed the product which is backward integrated with its in-house Active Pharmaceutical Ingredient (API). The company plans to commence commercial production of the product immediately after the approval is received, it added.More Related News